CORRECTED-UPDATE 1-Alnylam, Vir partner on RNAi-based hep B treatment
October 18, 2017 at 11:09 AM EDT
Oct 18 (Reuters) - Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.
